a public good project by the
Synthesis
Company
of California

© 2026

Mario H. Cardiel | doi.page

0 works0 citations0 h-index

Mario H. Cardiel

Universidad de Morelia(MX)Instituto Tecnológico de Morelia(MX)

Publications by Year

Research Areas

Rheumatoid Arthritis Research and Therapies, Systemic Lupus Erythematosus Research, Autoimmune and Inflammatory Disorders Research, Spondyloarthritis Studies and Treatments, Atherosclerosis and Cardiovascular Diseases

Most-Cited Works

→ Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial(2018)501 cited
→ Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus(2000)462 cited
→ The GLADEL Multinational Latin American Prospective Inception Cohort of 1,214 Patients With Systemic Lupus Erythematosus(2004)439 cited
→ Transancestral mapping and genetic load in systemic lupus erythematosus(2017)425 cited
→ Familial aggregation of systemic lupus erythematosus, rheumatoid arthritis, and other autoimmune diseases in 1,177 lupus patients from the GLADEL cohort(2005)418 cited
→ Epidemiology of the Rheumatic Diseases in Mexico. A Study of 5 Regions Based on the COPCORD Methodology(2011)296 cited

→ LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: Results from a randomized, double‐blind, placebo‐controlled study(2003)244 cited

→ Genome‐Wide Association Study in an Amerindian Ancestry Population Reveals Novel Systemic Lupus Erythematosus Risk Loci and the Role of European Admixture(2015)163 cited

How to measure health status in rheumatoid arthritis in non-English speaking patients: validation of a Spanish version of the Health Assessment Questionnaire Disability Index (Spanish HAQ-DI).(1993)

→ Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II)(2023)153 cited